Meet the Volunteers Behind the Programme
Our volunteers have very kindly dedicated their time, insight and expertise to helping shape the Annual Conference programme.
Dr Kirsty Wydenbach FFPM
VP, Head of Regulatory Strategy at Weatherden
Conference Event Chair
Kirsty has been the Head of Regulatory Strategy at Weatherden, a global integrated consultancy, since 2022. Kirsty joined Weatherden from the MHRA where she was an expert medical assessor in the Clinical Trials Unit for nearly 14 years, with particular expertise in advanced therapies, first-in-human trials and novel trial designs. During the Covid-19 pandemic, Kirsty worked on the UK Government Vaccine Taskforce, providing regulatory support to DHSC and NIHR. She currently chairs the Clinical Trial Science and Regulations Expert Group of FPM, is an expert on the Drug Development Advisory Board of CRO Simbec-Orion and is a senior lecturer for King’s College London.
Dr Harjeet Dhillon FFPM
Consultant Pharmaceutical Physician
Workshop Lead: Influencing Others Through Collaboration
Harjeet is a Consultant Pharmaceutical Physician and global Medical Affairs leader with over 20 years of experience across the pharmaceutical industry. She trained in Medicine at Oxford and London, and began her career in the NHS before moving into industry. Harjeet’s work at AbbVie and GSK has spanned country, regional and global roles, with a focus on bringing innovative medicines to patients with unmet need across several therapeutic areas.
She has led medical strategy from early pipeline through to brand maturity, driving patient-centred thinking, cross-functional partnership and innovation in everyday practice. Harjeet enjoys leading teams, building a culture of trust, and supporting the growth of pharmaceutical professionals. Harjeet is an Educational Supervisor for Pharmaceutical Medicine Specialty Training and a Revalidation Appraiser. She also contributes to FPM’s clinical trials and rare diseases expert groups.
Dr Nubli Fahimi
Chief Medical Officer, NovaPhase Clinical Research
Nubli has nearly a decade of industry experience spanning both clinical research and clinical development. He previously served as a Medical Director in Clinical Development at AstraZeneca and recently founded NovaPhase Clinical Research, where he holds the position of Chief Medical Officer.
Nubli is also the founder and Chair of the UK Pharmaceutical Medicine Physicians group, a non-profit organisation dedicated to supporting the transition of medical professionals into the pharmaceutical industry. Through this platform, he has successfully organised and led pharmaceutical physicians’ networking events over the past five years, fostering professional development and collaboration within the field.
Dr Samantha Goldman
Principal Consultant, Medical Director at Lucent Biopharma.
Samantha is an experienced operational, people & strategic Leader within the field of Medical Affairs with demonstrated success in regional & local roles as well as proven capabilities to work across multiple therapy areas including Cardiovascular, Diabetes, Neurology, Oncology, Respiratory & Pain. She is experienced also in market access, clinical development and regulatory submissions. She is motivated by leading & developing successful teams; developing & implementing medical affairs strategies across full product life cycle, including launch, as well as working with stakeholders across internal, external and alliance partners.
She enjoys nurturing talent to grow into leadership roles and creates medical strategies that improve patient outcomes.
Dr Nicholas Gollop MFPM
Pharmaceutical physician and Executive Medical Director at Novartis
Dr Nicholas Gollop is a pharmaceutical physician and Executive Medical Director at Novartis, where he leads cardiovascular development programmes and contributes to portfolio strategy and innovation. He has worked across clinical development, medical affairs, regulatory strategy, and product launches, with experience spanning small molecules, biologics, and gene therapies. He holds academic appointments at King’s College London and the University of Surrey. His interests include healthcare innovation and using science, data, and technology to improve patient outcomes and deliver better long-term value in healthcare systems.
Dr Emma Harvey FFPM
Vice-President of FPM
Debate Chair: Is the Current Pharma Model Sustainable?
Emma Harvey is a consultant pharmaceutical physician and Vice President of FPM. She joined Pharma in 1999 working in Big Pharma and small Biotech. She has built and led teams nationally and globally, leading pre- and peri-launch projects integrating commercial, medical affairs, regulatory, clinical development, pharmacovigilance and market access expertise to develop and implement strategic plans. With the CEO, she established the EDI Forum at FPM and has championed the cause of women in becoming Fellows of the Faculty. Interests include managing misinformation and ensuring equity of access to clinical trials for all.
Dr Lisa Moore-Ramdin FFPM
Senior Director, Global Medical and Scientific Affairs Lead, Neurosciences
Workshop Lead: Building Your Personal Impact
Plenary Session Chair: Bringing Children’s Perspectives & Guardian Voices into Clinical Research
Lisa obtained her MBBS from the University of the West Indies, Trinidad & Tobago and further specialized in paediatrics with an interest in neurology. After a decade of clinical practice within the West Indies and the UK NHS, she obtained her CCST in Pharmaceutical Medicine and dedicated the past 20 years to a career that spanned various medical affairs roles of increasing seniority across large pharma and small biotechs.
In her current role at Jazz Pharmaceuticals, she remains passionate about supporting people with epilepsy and rare neurological disorders by enabling research and development of approved medicines that improve the quality of life for patients and their caregivers.
Dr Michael Zaiac FFPM
Head of Medical Affairs in Oncology at Daiichi Sankyo
Workshop Lead: Managing AI in Pharma
Michael Zaiac is a physician-leader whose career has been shaped by a deep commitment to science, patients and people. Trained in the United Kingdom and Germany, he began in surgery before specialising in surgical oncology, caring for patients with breast cancer, sarcoma, melanoma and other malignancies. He later moved into industry to help translate scientific innovation into meaningful therapeutic advances. Michael has led teams across clinical research, development, commercial functions and medical affairs, supporting medicines in oncology and other major disease areas. He holds an MD, MBA, FRCS, FFPM, specialty registration and honorary GFMD, with publications across medicine and healthcare innovation.
